Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

Novel Interatrial Shunt Succeeds in HF Hemodynamic Study

News Conference News AHA 2017

Novel Interatrial Shunt Succeeds in HF Hemodynamic Study: REDUCE LAP-HF I

Michael O'Riordan

November 21, 2017

ACC Survey: More than One in Four Cardiologists Report Burnout

News Conference News

ACC Survey: More Than One in Four Cardiologists Report Burnout

November 20, 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

PRESERVE Puts the Kibosh on Approaches to Preventing Contrast-Associated AKI

News Conference News AHA 2017

PRESERVE Puts the Kibosh on Approaches to Preventing Contrast-Associated AKI

November 12, 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

November 01, 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

News Conference News ESC 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

September 01, 2017

Supplemental Oxygen Provides No Benefit to Patients With Suspected MI: DETO2X-AMI

News Conference News ESC 2017

Supplemental Oxygen Provides No Benefit to Patients With Suspected MI: DETO2X-AMI

Michael O'Riordan

August 28, 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

News Conference News ESC 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

August 27, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

Minority Women Face 50% Increased Risk of Death/MI After PCI Compared With White Men at 1 Year

News Conference News SCAI 2017

Minority Women Face 50% Increased Risk of Death/MI After PCI Compared With White Men at 1 Year

May 18, 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

News Conference News EAS 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Yael L. Maxwell

April 26, 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

News Conference News ACC 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

March 23, 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest

News Conference News ACC 2017

RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest

Yael L. Maxwell

March 20, 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

March 18, 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.